Judge’s unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake By: MarketWatch January 06, 2017 at 12:17 PM EST The decision could force Regeneron/Sanofi to stop selling their $14,000-a-year Praluent drug. Read More >> Related Stocks: Amgen Regeneron Pharmaceuticals Sanofi-Aventis S.A. ADR